Key result
Early identification of kidney disease through targeted case-finding and screening can protect kidney health, prevent disease progression, and reduce cardiovascular risk globally.
Early detection of chronic kidney disease through targeted case-finding or population screening, combined with treatments like SGLT2 inhibitors, is essential to reduce global cardiovascular and kidney disease burden.
Early identification of kidney disease can protect kidney health, prevent kidney disease progression and related complications, reduce cardiovascular disease risk, and decrease mortality. We must ask “ Are your kidneys ok ?” using serum creatinine to estimate kidney function and urine albumin to assess for kidney and endothelial damage. Evaluation for causes and risk factors for chronic kidney disease (CKD) includes testing for diabetes and measurement of blood pressure and body mass index (BMI). This World Kidney Day, we assert that case-finding in high-risk populations, or even population-level screening, can decrease the burden of kidney disease globally. Early-stage CKD is asymptomatic and simple to test for and recent paradigm-shifting CKD treatments such as sodium glucose co-transporter-2 inhibitors dramatically improve outcomes and favor the cost-benefit analysis for screening or case-finding programs. Despite this, numerous barriers exist, including resource allocation, healthcare funding, healthcare infrastructure, and healthcare-professional and population awareness of kidney disease. Coordinated efforts by major kidney non-governmental organizations to prioritize the kidney health agenda for governments and aligning early detection efforts with other current programs will maximize efficiencies.
No takes yet. Share an insight, caveat, or question.
Vassalotti et al. (2025) conducted an editorial in Chronic Kidney Disease. Early detection and screening was evaluated. Early identification of kidney disease through targeted case-finding and screening can protect kidney health, prevent disease progression, and reduce cardiovascular risk globally.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: